| Votrient (pazopanib) / Novartis, BeiGene |
NCT01975519: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2a | 111 | US | TRC105 and Pazopanib, Chimeric Antibody (TRC105) to CD105, Votrient | Tracon Pharmaceuticals Inc. | Advanced Soft Tissue Sarcoma | 03/19 | 03/19 | | |
|
|
|
|
NCT01391611: Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) |
|
|
| Terminated | 2 | 25 | US | Pazopanib, Votrient | Kristen Ganjoo, GlaxoSmithKline | Gastrointestinal Stromal Tumor (GIST) | 06/13 | 12/13 | | |
NCT00297258: Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma |
|
|
| Completed | 2 | 148 | Europe | pazopanib, GW786034 | GlaxoSmithKline | Sarcoma, Soft Tissue | 02/14 | 02/14 | | |
2004-004378-10: Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists. |
|
|
| Completed | 2 | 148 | Europe | GW786034, GW786034, Tablet | GlaxoSmithKline Research & Development Ltd | Advanced and/or metastatic Soft Tissue Sarcoma | | | | |
| Terminated | 2 | 23 | Europe | Pazopanib | Assistance Publique - Hôpitaux de Paris, GlaxoSmithKline | Dermatofibrosarcomas of DARIER FERRAND(DFSP) | 04/14 | 04/14 | | |
| Completed | 2 | 81 | Europe | Pazopanib, Best supportive care | Centre Leon Berard, GlaxoSmithKline | GIST | 04/14 | 02/16 | | |
|
NCT01506596: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma |
|
|
| Completed | 2 | 42 | US | pazopanib, Votrient | Vector Oncology, Novartis | Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma | 10/14 | 03/16 | | |
| Completed | 2 | 72 | Europe | Pazopanib, Votrient | Scandinavian Sarcoma Group, GlaxoSmithKline | Gastrointestinal Stromal Tumors | 01/15 | 11/16 | | |
2009-017261-32: Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma |
|
|
| Completed | 2 | 90 | Europe | Gemcitabine, Gemcitabine, Film-coated tablet, Concentrate for solution for infusion, Votrient 400 mg film-coated tablets, Votrient 200 mg film-coated tablets | Martin-Luther-Universität Halle-Wittenberg, GlaxoSmithKline GmbH & Co.KG, Aspen Bad Oldesloe GmbH, Martin Luther Universität Halle (Saale) | Relapsed or metastatic soft tissue sarcoma, Relapsed or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 2 | 21 | Europe | pazopanib, Votrient | Heidelberg University, Universitätsmedizin Mannheim, Klinikum Frankfurt Höchst, German Cancer Research Center, GlaxoSmithKline, University Hospital Heidelberg | Sarcoma, Soft-tissue | 10/16 | 10/16 | | |
NCT01759303: Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung |
|
|
| Terminated | 2 | 12 | US | pazopanib, Votrient | George Clinical Pty Ltd, Novartis | Osteosarcoma, Metastatic Osteosarcoma | 01/17 | 05/17 | | |
NCT03149120: Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas |
|
|
| Withdrawn | 2 | 0 | US | Nivolumab, Opdivo, Pazopanib, Votrient | NYU Langone Health, Bristol-Myers Squibb | Soft Tissue Sarcomas | 08/17 | 06/22 | | |
| Withdrawn | 2 | 0 | US | Pazopanib | Gynecologic Oncology Group, GlaxoSmithKline | Uterine Leiomyosarcoma | 01/18 | | | |
| Completed | 2 | 47 | Europe, US | pazopanib, Votrient | George Clinical Pty Ltd, GlaxoSmithKline | Chondrosarcoma, Metastatic Chondrosarcoma | 02/18 | 02/18 | | |
| Completed | 2 | 52 | Europe | Pazopanib | Grupo Espanol de Investigacion en Sarcomas, GlaxoSmithKline | Advanced and / or Metastatic Liposarcoma | 03/18 | 03/18 | | |
NCT02357810: Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas |
|
|
| Completed | 2 | 178 | US | Pazopanib Hydrochloride, GW786034B, Votrient, Oral Topotecan Hydrochloride, Hycamtin Capsules, Oral Hycamtin, Laboratory Biomarker Analysis | Northwestern University, GlaxoSmithKline, National Cancer Institute (NCI) | Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma | 04/18 | 10/21 | | |
NCT02367651: Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma |
|
|
| Withdrawn | 2 | 0 | US, RoW | Pazopanib 800 mg, Placebo | GlaxoSmithKline | Sarcoma, Soft Tissue | 05/18 | 05/18 | | |
NCT01593748: A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2 | 90 | US | Gemcitabine and Pazopanib, Gemcitabine and Docetaxel | Medical University of South Carolina, Novartis | Sarcoma | 04/19 | 04/19 | | |
NCT02300545: Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy |
|
|
| Completed | 2 | 56 | US | Pazopanib, GW786034, Votrien | Washington University School of Medicine, Novartis Pharmaceuticals | Sarcoma, Soft Tissue, Soft Tissue Sarcoma | 05/19 | 07/20 | | |
NCT01532687: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma |
|
|
| Completed | 2 | 54 | US | Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pazopanib, GW786034, Pazopanib Hydrochloride, GW786034B, Votrient, Placebo Administration | OHSU Knight Cancer Institute, Novartis Pharmaceuticals, Oregon Health and Science University | Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7 | 10/19 | 10/19 | | |
| Terminated | 2 | 26 | Europe | Pazopanib + Paclitaxel | Heidelberg University, Universitätsmedizin Mannheim, Helios Klinikum Berlin-Buch, University Hospital Dresden, Universitätsklinikum Hamburg-Eppendorf, University Hospital, Essen, Hannover Medical School, Klinikum der Universitaet Muenchen, Grosshadern, Medical University of Vienna, Medical University of Graz, Medical University Innsbruck, Novartis Pharmaceuticals | Angiosarcoma | 12/19 | 07/20 | | |
NCT02342600: SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) |
|
|
| Withdrawn | 2 | 0 | NA | Pazopanib, Votrient, Trametinib, Mekinist | Sarcoma Alliance for Research through Collaboration, Novartis | Gastrointestinal Stromal Tumors | 01/20 | | | |
| Active, not recruiting | 2 | 58 | Europe | Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient | North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH | Leiomyosarcoma or Carcinosarcoma | 12/24 | 12/24 | | |
NCT01719302: Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma |
|
|
| Completed | 1/2 | 6 | US | Gemcitabine, Gemzar, Docetaxel, Taxotere, Pazopanib, Votrient | University of Vermont, Novartis | Stage III Adult Soft Tissue Sarcoma | 04/15 | 04/15 | | |
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas |
|
|
| Active, not recruiting | 1/2 | 19 | US | Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient | University of Washington, Aadi Bioscience, Inc. | Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma | 11/22 | 02/25 | | |
AMPHISARC, NCT05180695: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas |
|
|
| Recruiting | 1/2 | 58 | Europe | Pazopanib, Votrient, HDM201, siremadlin | Centre Leon Berard, Novartis, National Cancer Institute, France | Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | 01/26 | 07/26 | | |
